All In Biotech

Drug Trial Radar · NCT03174236

First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition

Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Sep 4, 2017

Primary completion

Jan 31, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University College, London; London School of Hygiene and Tropical Medicine; Swansea Trials Unit; Kenya Medical Research Institute; KEMRI-Wellcome Trust Collaborative Research Program
First posted
Jun 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 months, up to 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Children with severe malnutrition who are admitted sick to hospitals have a high mortality(death rate), usually because of infection. All children with severe malnutrition admitted to hospitals are treated with antibiotics(medication used to kill bacteria). However, the current antibiotics used in hospitals may not be the most effective. It is possible that the antibiotics that are currently used after initial antibiotics should be used first. No studies have been carried out to determine if the current antibiotics used for treating malnourished children who are sick and admitted in hospital are the most appropriate. The aim of this study is to find out if a changed antibiotic system for children with malnutrition is safe, reduces the risk of death and improves nutritional recovery.

Conditions

  • Malnutrition Severe
  • Antibiotic Resistance
  • Antibiotic Toxicity

Interventions

  • CeftriaxoneDrug

    Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.

  • Benzyl penicillinDrug

    The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.

  • MetronidazoleDrug

    The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, "however, the efficacy of this treatment has not been established in clinical trials."

  • PlaceboOther

    Suspension manufactured to match metronidazole

  • GentamicinDrug

    The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 90 days after enrolment.

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • KEMRI WT Clinical Trials Facility

    Kilifi, Kenya

  • Kilifi County Hospital

    Kilifi, Kenya

  • Coast General Hospital - Study site

    Mombasa, Kenya

  • Mbagathi District Hospital

    Nairobi, Kenya

  • Mbagathi Hospital

    Nairobi, Kenya

  • Kilifi County Hospital

    Kilifi, Coast, Kenya

  • Kemri Wellcome Trust Research Programme

    Kilifi, Coast Province, Kenya

  • Mbale Regional Referral Hospital

    Mbale, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.